GLGialih Lin

Gialih Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gialih Lin has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Shyh-Ying Chiou

    A Department of Neurosurgery , Tungs' Taichung MetroHarbor Hospital, Wuchi , Taichung 435 , Taiwan

    5 shared publications
  • Shyh‐Ying Chiou

    Department of Neurosurgery, Chung Shan Medical University Hospital, Taichung 402, Taiwan

    5 shared publications
  • Ming‐Cheng Lin

    Department of Internal Medicine, Chung Shan Medical University Hospital, School of Medicine, Chung-Shan Medical University, Taichung 402, Taiwan

    4 shared publications
  • Chuan‐Fu Huang

    Department of Neurosurgery, Chung Shan Medical University Hospital, Taichung 402, Taiwan

    3 shared publications
  • Chung‐Sheng Lin

    Institute of Medicine, Division of Cardiology, Chung-Shan Medical University Hospital, Taichung 402, Taiwan, R.O.C.

    3 shared publications
  • Chun‐Ping Lu

    Institute of Biochemistry, Academia Sinica, Taipei, Taiwan

    3 shared publications

Latest Publications

  • Molecular docking of different inhibitors and activators to butyrylcholinesterase

    by Shyh-Ying Chiou, Tzu-Ting Weng, Gin-Zen Lin, Ren-Jie Lu, Shuo-Yung Jian, Gialih Lin

    There are three major active sites of butyrylcholinesterase: catalytic site, peripheral site, and activator site. In this study, pseudosubstrate inhibitors, 1,3,5-alkylcarbamyloxybenzenes (1–11), were designed as the catalytic site directed inhibitors of the enzyme. Automated docking of 1,3,5-tri-n-octylcarbamyloxybenzene 1 into the X-ray crystal structure of butyrylcholinesterase suggested that the configuration of the inhibitor in the enzyme complex is in the (1,3,5)-(cis,trans,trans)-form. Thus, the cis n-octylcarbamyl group of 1 extended itself to the peripheral site; furthermore, two trans n-octylcarbamyl moieties of 1 shielded W82 of the anionic site. 5-N-n-Butylcarbamyloxyresorcinol (12) was further used to characterize the butyryl group binding site of the catalytic site. Automated docking of 12 into the enzyme showed that the best bound rotamer of the inhibitor in the enzyme complex was the trans form. Moreover, the butylcarbamyl moiety of 12 was bound well into the butyryl group binding site of the enzyme. Docking of cage amines into the enzyme indicated that these compounds were bound into the peripheral site of the enzyme. We also found that a small cave, located outside the enzyme around A277-Y282, might play an important role in the activation of the enzyme. Two activators of butyrylcholinesterase, n-butyl-N-carbamyloxy-3,3-dimethylbutane and 2,4,6-trinitrotoluene, were docked well into the above-mentioned cave.


  • Open Access

    Synthesis and evaluation of a new series of tri‐, di‐, and mono‐N‐alkylcarbamylphloroglucinols as conformationally constrained inhibitors of cholesterol esterase

    by Ming‐Cheng Lin, Gin‐Zen Lin, Ching‐In Hwang, Shuo‐Yung Jian, James Lin, Yu‐Fong Shen, Gialih Lin

    1,3,5‐Tri‐N‐alkylcarbamylphloroglucinols (1–4) are synthesized as conformationally constrained analogs of triacylglycerols (TGs) to probe Jenck's proximity effect in the cholesterol esterase inhibition. For the cholesterol esterase inhibition, inhibitors 1–4 are 220–760‐fold more potent than 1,2,3‐tri‐N‐alkylcarbamylglycerols (13–15) that are substrate analogs of TG. Comparison of tridentate inhibitors 1–4, bidentate inhibitors 3,5‐di‐N‐n‐alkylcarbamyloxyphenols (5–8) and monodentate inhibitors 5‐N‐n‐alkylcarbamyloxyresorcinols (9–12) indicates that inhibitory potencies are as followed: tridentate inhibitor > bidentate inhibitor > monodentate inhibitor. The log ki and pKi values of tridentate inhibitors, bidentate inhibitors, and monodentate inhibitors are linearly correlated with the alkyl chain length indicating a common mechanism in each inhibition. Also, positive slopes of these correlations indicate that the longer chain inhibitors bind more tightly to the enzyme than the shorter ones. Molecular dockings of tridentate 1, bidentate 5, and monodentate 9 into the X‐ray crystal structure of cholesterol esterase suggest that one carbamyl group in the cis form of the inhibitor binds to the acyl chain‐binding site of the enzyme. The second carbamyl groups in the trans forms of inhibitors 1 and 5 bind to the second acyl chain‐binding site of the enzyme. The third carbamyl group in the trans form of inhibitor 1 binds to the third acyl chain‐binding site of the enzyme. Moreover, the configuration of the inhibitor in the enzyme‐inhibitor complex is the (1,3,5)‐(cis, trans, trans)‐tricarbamate form that mimics the (+gauche, −gauche)‐conformation of TG.


  • Kinetics and Protein‐Inhibitor Docking Studies of Enantiomers of exo‐2‐Norbornyl‐N‐n‐butylcarbamates as Pseudomonas Lipase Inhibitors to Probe the Enantioselectivity of the Enzyme

    by Yu‐Fang Shen, Gialih Lin

    The Pseudomonas species lipase inhibition shows enantioselectivity for R‐enantiomer over S‐enantiomer of exo‐2‐norbornyl‐N‐n‐butylcarbamates. R‐, S‐, and racemic‐exo‐2‐norbornyl‐N‐n‐butylcarbamates are all characterized as pseudo substrate inhibitors of the enzyme. Thus, the mechanism for Pseudomonas species lipase‐catalyzed hydrolysis of the inhibitor is formation of the first enzyme‐inhibitor Michaelis complex via nucleophilic attack of the active site serine to the inhibitor (Ki step) then formation of the butylcarbamyl enzyme intermediate from this complex (k2 step). Comparison of bimolecular rate constants (ki = k2 / Ki) of the inhibitors indicates that R‐enantiomer is 1.8 times more potent than S‐enantiomer. Thus, Pseudomonas species lipase shows enantioselectivity of 1.8 for R‐exo‐2‐norbornyl‐N‐n‐butyl‐carbamate over S‐exo‐2‐norbornyl‐N‐n‐butylcarbamate. Protein‐ligand interaction studies on both enantiomers of exo‐2‐norbornyl‐N‐n‐butylcarbamate as inhibitors of Pseudomonas species lipase using AutoDock suggest that R‐enantiomer binds more tightly into the active site of the enzyme than S‐enantiomer. The norbornyl ring of S‐exo‐2‐norbornyl‐N‐n‐butylcarbamate is repulsive to Ser 82 and His 251 of the catalytic triad as well as to Met 16 of the oxyanion hole. These repulsions may create few unfavorable interactions between S‐exo‐2‐norbornyl‐N‐n‐butylcarbamate and the enzyme and make this inhibitor a less potent one.


  • Stereo-specific inhibition of acetyl- and butyryl-cholinesterases by enantiomers of cis,cis-decahydro-2-naphthyl-N-n-butylcarbamate

    by Ming-Cheng Lin, Shyh-Jei Yeh, I-Ru Chen, Gialih Lin

    Enantiomers of cis,cis-decahydro-2-naphthyl-N-n-butylcarbamate show stereo-specific inhibition for acetylcholinesterase and butyrylcholinesterase. For both inhibition reaction, (2S,4aR,8aS)-cis,cis-decahydro-2-naphthyl-N-n- butylcarbamate is more potent than (2R,4aS,8aR)-cis,cis-decahydro-2-naphthyl-N-n-butylcarbamate. Optically pure (2S,4aR,8aS)-(−)- and (2R,4aS,8aR)-(+)-cis,cis-decahydro-2-naphthols are resolved by the porcine pancreatic lipase-catalyzed acetylation of decahydro-2-naphthols with vinyl acetate. Absolute configurations and the enantiomeric excess values of (2S,4aR,8aS)-(−)- and (2R,4aS,8aR)-(+)-cis,cis-decahydro-2-naphthols are determined from the 19F NMR spectra of their Mosher's ester derivatives. We fail to resolve (2S,4aR,8aR)- and (2R,4aS,8aS)-trans,cis-decahydro-2-naphthols from the porcine pancreatic lipase-catalyzed acetylation of decahydro-2-naphthols with vinyl acetate. © 2011 Wiley Periodicals, Inc. J Biochem Mol Toxicol 25:330–339, 2011; View this article online at wileyonlinelibrary.com. DOI 10.1002/jbt.20394

  • Stereoselective Inhibition of Cholesterol Esterase by Enantiomers of exo- and endo-2-Norbornyl-N–n-butylcarbamates

    by Ming-Cheng Lin, Shyh-Jei Yeh, I-Ru Chen, Gialih Lin

    Four stereoisomers of 2-norbornyl-N–n-butylcarbamates are characterized as the pseudo substrate inhibitors of cholesterol esterase. Cholesterol esterase shows enantioselective inhibition for enantiomers of exo- and endo-2-norbornyl-N–n-butylcarbamates. For the inhibitions by (R)-(+)- and (S)-(−)-exo-2-norbornyl-N–n-butylcarbamates, the R-enantiomer is 6.8 times more potent than the S-enantiomer. For the inhibitions by (R)-(+)- and (S)-(−)-endo-2-norbornyl-N–n-butyl-carbamates, the S-enantiomer is 4.6 times more potent than the R-enantiomer. The enzyme-inhibitor complex models have been proposed to explain these different enantioselectivities.


  • Comparison of active sites of butyrylcholinesterase and acetylcholinesterase based on inhibition by geometric isomers of benzene‐di‐N‐substituted carbamates

    by Shyh‐Ying Chiou, Chuan‐Fu Huang, Mei‐Ting Hwang, Gialih Lin

    We have reported that benzene‐1,2‐, 1,3‐, and 1,4‐di‐N‐substituted carbamates (1–15) are characterized as the conformationally constrained inhibitors of acetylcholinesterase and mimic gauche, eclipsed, and anti‐conformations of acetylcholine, respectively (J Biochem Mol Toxicol 2007;21:348–353). We further report the inhibition of butyrylcholinesterase by these inhibitors. Carbamates 1–15 are also characterized as the pseudosubstrate inhibitors of butyrylcholinesterase as in the acetylcholinesterase catalysis. Benzene‐1,4‐di‐N‐n‐hexylcarbamate (12) and benzene‐1,4‐di‐N‐n‐octylcarbamate (13) are the two most potent inhibitors of butyrylcholinesterase among inhibitors 1–15. These two para compounds, with the angle of 180° between two C(benzene)O bonds, mimic the preferable anti CO/CN conformers for the choline ethylene backbone of butyrylcholine during the butyrylcholinesterase catalysis. The second n‐hexylcarbamyl or n‐octylcarbamyl moiety of inhibitors 12 and 13 is proposed to bind tightly to the peripheral anionic site of butyrylcholinesterase from molecular modeling. Butyrylcholinesterase prefers para‐carbamates to ortho‐ and meta‐carbamates, whereas acetylcholinesterase prefers para‐ and meta‐carbamates to ortho‐carbamates. This result implies that the anionic site of butyrylcholinesterase is relatively smaller than that of acetylcholinesterase because meta‐carbamates, which may bind to the anionic sites of both enzymes, are not potent inhibitors of butyrylcholinesterase. © 2009 Wiley Periodicals, Inc. J Biochem Mol Toxicol 23:303–308, 2009; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jbt.20286


  • Synthesis of enantiomers ofexo‐2‐norbornyl‐N‐n‐butylcarbamate andendo‐2‐norbornyl‐N‐n‐butylcarbamate for stereoselective inhibition of acetylcholinesterase

    by Shyh‐Ying Chiou, Chuan‐Fu Huang, Shyh‐Jei Yeh, I‐Ru Chen, Gialih Lin

    The acetylcholinesterase inhibition by enantiomers ofexo‐ andendo‐2‐norbornyl‐N‐n‐butylcarbamates shows high stereoselelectivity. For the acetylcholinesterase inhibitions by (R)‐(+)‐ and (S)‐(−)‐exo‐2‐norbornyl‐N‐n‐butylcarbamates, theR‐enantiomer is more potent than theS‐enantiomer. But, for the acetylcholinesterase inhibitions by (R)‐(+)‐ and (S)‐(−)‐endo‐2‐norbornyl‐N‐n‐butylcarbamates, theS‐enantiomer is more potent than theR‐enantiomer. Optically pure (R)‐(+)‐exo‐,(S)‐(−)‐exo‐, (R)‐(+)‐endo‐, and (S)‐(−)‐endo‐2‐norbornyl‐N‐n‐butylcarbamates are synthesized from condensations of optically pure (R)‐(+)‐exo‐,(S)‐(−)‐exo‐, (R)‐(+)‐endo‐, and (S)‐(−)‐endo‐2‐norborneols withn‐butyl isocyanate, respectively. Optically pure norborneols are obtained from kinetic resolutions of their racemic esters by lipase catalysis in organic solvent. Chirality 2010.


  • Activation Mechanisms of Butyrylcholinesterase by 2,4,6-Trinitrotoluene, 3,3-Dimethylbutyl-N-n-butylcarbamate, and 2-Trimethylsilyl-ethyl-N-n-butylcarbamate

    by Shyh-Ying Chiou, Yon-Gi Wu, Gialih Lin

    The goal of this work was to propose a possible mechanism for the butyrylcholinesterase activation by 2,4,6-trinitrotoluene (TNT), 3,3-dimethylbutyl-N-n-butylcarbamate (1), and 2-trimethylsilyl-ethyl-N-n-butylcarbamate (2). Kinetically, TNT, and compounds 1 and 2 were characterized as the nonessential activators of butyrylcholinesterase. TNT, and compounds 1 and 2 were hydrophobic compounds and were proposed to bind to the hydrophobic activator binding site, which was located outside the active site gorge of the enzyme. The conformational change from a normal active site gorge to a more accessible active site gorge of the enzyme was proposed after binding of TNT, and compounds 1 and 2 to the activator binding site of the enzyme. Therefore, TNT, and compounds 1 and 2 may act as the excess of butyrylcholine in the substrate activator for the butyrylcholinesterase catalyzed reactions.